Uncategorized

Tyler Is growing up

Here it is; “Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the planned acquisition of privately-held Companion Medical, manufacturer of InPen — the only U.S. FDA-cleared smart insulin pen system paired with an integrated diabetes management app on the market. The addition of Companion Medical’s InPen to the Medtronic portfolio expands the company’s ability to serve people where they are in their diabetes journey and offer them a...

A game of musical chairs

We are still trying to figure out the logic behind yesterday’s news that Ascensia has partnered with Senseonics. As we noted yesterday this deal doesn’t seem to have a solid business rational behind it. The best we can figure after giving it more thought is that this deal was driven more by fear than any solid business rational. That the CGM market has become so hot, that the market is...

Not Dead Just Yet

This afternoon after the market closed Senseonics, not only released second quarter results but a new agreement with Ascensia, per the press release; “Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the formation of a strategic partnership with Ascensia Diabetes Care (Ascensia), through a commercialization and collaboration agreement, which...

Fools or Visionaries?

Laurence Peter once said; “You can fool some of the people all of the time and all of the people some of the time, but you can make a damn fool of yourself any old time.” Given the reaction to the Livongo Teladoc merger we’re beginning to think Mr. Peter might be right. Reading through the various analysis of the deal this is either the beginning of a revolution or...

Good but not great

There is no question a trend has developed with each earnings release during COVID. At first companies were basically clueless about what the true impact of COVID would be. Some decided rather than guess the prudent move was to pull future guidance. As we moved into the second quarter the COVID picture became clearer and for many the impact wasn’t as bad as first thought. Those who pulled guidance reinstated...

The transformation continues

Looking at the results released by Novo Nordisk this morning and listening to the earnings call the transformation initiated by the company continues to move ahead. Like their main competitor Lilly, Novo is also adjusting to the impact of COVID. The good news is that things aren’t as bad as initially anticipated. The fact is until COVID is gone everyone is adjusting to this new normal and the new normal...

Will it actually happen?

As expected everyone in the mainstream media sees the Livongo/Teladoc merger as a watershed event for digital health. Ironically the Street wasn't that impressed as Livongo shares fell by over 11% while Teladoc shares fell over 19%. The real question we have is will these two companies actually consummate this marriage or will one of the nuptials get cold feet at the alter? According to everything we have read the deal...

There were only two options

In news that will send shockwaves through the digital health world Teladoc and Livongo this morning announced a merger which values the company at an incredible $18.5 Billion. Per the Teladoc press release: “Teladoc Health (TDOC), the global leader in virtual care, and Livongo (LVGO), the leading Applied Health Signals company – today announced that they have entered into a definitive merger agreement. This merger represents a transformational opportunity to improve...

Refreshingly Predictable

Given the unpredictable world COVID has created it’s nice to see that some predictability has returned. Per the earnings release from Tandem; “We are reinstating the sales guidance we set at the beginning of 2020 based on the continued strong worldwide demand for our t:slim X2 insulin pump,” said Leigh Vosseller, executive vice president and chief financial officer. “While being mindful of the unpredictable nature of the current pandemic, our confidence...

No surprises

As we anticipated earnings season during COVID is falling into a predictable pattern and the results released by Lilly this morning are an example. During the first quarter patients stocked up on prescription medications such as insulin. This resulted in higher than anticipated sales during the quarter a trend which reversed itself in the second quarter as sales of Humalog declined by 18%. As the company noted in the earnings press...